ALKS vs ELAN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ALKS · Alkermes$45.90 ▲ 3.05%
ELAN · Elanco Animal Health$25.74 ▲ 8.70%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ALKS +40.6%
- ELAN +15.6%
Head to head
| Metric | ALKS | ELAN |
|---|---|---|
| Price | $45.90 | $25.74 |
| Change today | ▲ 3.05% | ▲ 8.70% |
| Market cap | $7.71B | $12.86B |
| Return, 3 months | -7.1% | +15.5% |
| Return, year to date | +64.0% | +13.7% |
| Return, 1 year | +39.6% | +19.8% |
| P/E (TTM) | – | – |
| P/B | 4.1 | 2.0 |
| P/E percentile vs own 5y | 97th | 11th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +27.0% | +10.2% |
| Net profit growth (YoY) | -99.4% | +390.9% |
| Gross margin | 84.6% | 55.4% |
| Operating margin | 8.6% | 6.6% |
| Net margin | 4.0% | -4.0% |
| Return on equity | 3.9% | -3.0% |
| Analyst target vs. price | +30.3% | +20.1% |
| Analyst buy share | 73% | 86% |
| RSI (14) | 60 | 65 |
| 30-day volatility | 31.6% | 42.3% |
| Max drawdown, 1 year | -29.2% | -26.2% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ELAN is the largest of the group by market value.
- ALKS has returned the most over the past year.
- ALKS is growing revenue fastest.
- ALKS keeps the most profit per dollar of sales.
- ALKS has been the calmest stock over the last 30 days.